Over the past ten years, several biologic agents have been marketed following randomized controlled trials
in patients with psoriasis for the indication of plaque psoriasis and/or psoriatic arthritis1,2 for adalimumab,3,4 alefacept,5,6 efalizumab,7,8 etanercept,9,10 infliximab,11,12 and ustekinumab.13-15 With the advent of these newer biologic agents, an even wider array of treatment options in addition to established conventional systemic treatments or phototherapies
are available to dermatologists for patients with psoriasis. The long-term safety of these therapies in plaque psoriasis in actual clinical use has not been fully characterized, prompting the development of several types of patient registries. These registries serve an important role,16 often replicating randomized
controlled trial results in a broader population of interest and may detect less common safety events that were not identified
in clinical studies.
Based on the method of data collection, registry studies include
three important categories (voluntary, retrospective, and prospective). In a voluntary registry, events are reported by health-care providers or patients and entered into regulatory, national, or manufacturer databases. In a retrospective registry,
↑ back to top